报告题目：美中工业药物制剂研发的流程及区别
报告时间：2015年9月16日（周三）15：30-17：30
报告地点：图书馆五楼第二学术报告厅
报 告 人：李守峰 博士
（上海奥科达生物医药科技有限公司CEO）
主 持 人：唐星 教授
主办单位：药剂学科
研究生处（学科建设办公室）
辽宁省研究生现代药物领域创新与交流中心
聆听无涯论坛 拓宽学术视野
欢迎各位老师和同学们踊跃参加！
报告人简介
Dr. Shoufeng Li is CEO of Aucta Pharmaceuticals, LLC, an early stage start-up focusing on new drug product development and niche generic products. Aucta was co-founded by Dr. Li with headquarter in North Burnswick, NJ and operations in both NJ and Shanghai, China.
The mission of Aucta Pharmaceuticals is to develop better medicines to improve patients’ quality of life, with particular focus on the underserved populations including pediatric, geriatric and psychiatric patients. Our therapeutic focuses cover Central Nervous System (CNS), Infectious Diseases and Oncology.
Since its inception, Aucta pharmaceuticals has grown its business rapidly by providing R&D service based on its proprietary technologies, or out-licensing Aucta portfolio products in specific market(s). Aucta has expanded quickly to its current size of close to 30 employees, attracted talents from various disciplines and recently secured first round of VC funding. Aucta has significant late stage project management and regulatory skills to bring a product to market.
Prior to founding Aucta Pharmaceuticals, Dr. Li is Director, Technical Project Leader at Novartis Pharmaceuticals Corporation at East Hanover, NJ, where he was managing a multidisciplinary project teams, he was responsible for late phase project management and represent CMC function in global project team (GPT). Dr. Li has over 15 years of multi-national industrial product development experience in both small molecule and peptide/proteins delivery.
Dr. Li's interest and area of expertise is in 505(b)(2) product development and in vitro - in vivo correlation, he has been instrumental in overcoming multiple difficult to formulate bioequivalent products during his tenure at Novartis and was awarded Novartis Leading Scientist in 2007. He has been invited speakers in international forum for multiple occasions, and has over 30 peer reviewed research articles, reviews and patents. Dr. Li holds Ph.D. in Pharmaceutics and M.S. in Statistics from Rutgers University. He has been actively involved professionally in AAPS, SAPA and BayHelix.
